Currently, WT1 vaccines against leukemia, breast cancer, lung cancer, and pancreatic cancer are undergoing phase I or II clinical trials, and their efficacy and adverse reactions are also being under investigation. This evidence concerns the gene WT1 and familial pancreatic carcinoma.